Literature DB >> 19318482

Mathematical modeling of herpes simplex virus distribution in solid tumors: implications for cancer gene therapy.

Wilson Mok1, Triantafyllos Stylianopoulos, Yves Boucher, Rakesh K Jain.   

Abstract

PURPOSE: Although oncolytic viral vectors show promise for the treatment of various cancers, ineffective initial distribution and propagation throughout the tumor mass often limit the therapeutic response. A mathematical model is developed to describe the spread of herpes simplex virus from the initial injection site. EXPERIMENTAL
DESIGN: The tumor is modeled as a sphere of radius R. The model incorporates reversible binding, interstitial diffusion, viral degradation, and internalization and physiologic parameters. Three species are considered as follows: free interstitial virus, virus bound to cell surfaces, and internalized virus.
RESULTS: This analysis reveals that both rapid binding and internalization as well as hindered diffusion contain the virus to the initial injection volume, with negligible spread to the surrounding tissue. Unfortunately, increasing the dose to saturate receptors and promote diffusion throughout the tumor is not a viable option: the concentration necessary would likely compromise safety. However, targeted modifications to the virus that decrease the binding affinity have the potential to increase the number of infected cells by 1.5-fold or more. An increase in the effective diffusion coefficient can result in similar gains.
CONCLUSIONS: This analysis suggests criteria by which the potential response of a tumor to oncolytic herpes simplex virus therapy can be assessed. Furthermore, it reveals the potential of modifications to the vector delivery method, physicochemical properties of the virus, and tumor extracellular matrix composition to enhance efficacy.

Entities:  

Mesh:

Year:  2009        PMID: 19318482      PMCID: PMC2872130          DOI: 10.1158/1078-0432.CCR-08-2082

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  47 in total

1.  A thermodynamic characterization of the binding of thrombin inhibitors to human thrombin, combining biosensor technology, stopped-flow spectrophotometry, and microcalorimetry.

Authors:  Johanna Deinum; Lars Gustavsson; Erika Gyzander; Mari Kullman-Magnusson; Asa Edström; Robert Karlsson
Journal:  Anal Biochem       Date:  2002-01-15       Impact factor: 3.365

Review 2.  Herpesviruses and heparan sulfate: an intimate relationship in aid of viral entry.

Authors:  D Shukla; P G Spear
Journal:  J Clin Invest       Date:  2001-08       Impact factor: 14.808

3.  Role of tumor-host interactions in interstitial diffusion of macromolecules: cranial vs. subcutaneous tumors.

Authors:  A Pluen; Y Boucher; S Ramanujan; T D McKee; T Gohongi; E di Tomaso; E B Brown; Y Izumi; R B Campbell; D A Berk; R K Jain
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-27       Impact factor: 11.205

4.  Viruses as antitumor weapons: defining conditions for tumor remission.

Authors:  D Wodarz
Journal:  Cancer Res       Date:  2001-04-15       Impact factor: 12.701

5.  Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer.

Authors:  J Nemunaitis; F Khuri; I Ganly; J Arseneau; M Posner; E Vokes; J Kuhn; T McCarty; S Landers; A Blackburn; L Romel; B Randlev; S Kaye; D Kirn
Journal:  J Clin Oncol       Date:  2001-01-15       Impact factor: 44.544

6.  Kinetic analysis of glycoprotein C of herpes simplex virus types 1 and 2 binding to heparin, heparan sulfate, and complement component C3b.

Authors:  Ann H Rux; Huan Lou; John D Lambris; Harvey M Friedman; Roselyn J Eisenberg; Gary H Cohen
Journal:  Virology       Date:  2002-03-15       Impact factor: 3.616

Review 7.  Delivery of molecular and cellular medicine to solid tumors.

Authors:  R K Jain
Journal:  Adv Drug Deliv Rev       Date:  2001-03-01       Impact factor: 15.470

8.  Role of extracellular matrix assembly in interstitial transport in solid tumors.

Authors:  P A Netti; D A Berk; M A Swartz; A J Grodzinsky; R K Jain
Journal:  Cancer Res       Date:  2000-05-01       Impact factor: 12.701

9.  Direct comparison of binding equilibrium, thermodynamic, and rate constants determined by surface- and solution-based biophysical methods.

Authors:  Yasmina S N Day; Cheryl L Baird; Rebecca L Rich; David G Myszka
Journal:  Protein Sci       Date:  2002-05       Impact factor: 6.725

10.  Prerequisites for effective adenovirus mediated gene therapy of colorectal liver metastases in the rat using an intracellular neutralizing antibody fragment to p21-Ras.

Authors:  B van Etten; T L M ten Hagen; M R de Vries; G Ambagtsheer; T Huet; A M M Eggermont
Journal:  Br J Cancer       Date:  2002-02-01       Impact factor: 7.640

View more
  32 in total

Review 1.  Gene therapy: a pharmacokinetic/pharmacodynamic modelling overview.

Authors:  Zinnia P Parra-Guillén; Gloria González-Aseguinolaza; Pedro Berraondo; Iñaki F Trocóniz
Journal:  Pharm Res       Date:  2010-04-13       Impact factor: 4.200

2.  Actin-resistant DNAse I Expression From Oncolytic Adenovirus Enadenotucirev Enhances Its Intratumoral Spread and Reduces Tumor Growth.

Authors:  Alison Tedcastle; Sam Illingworth; Alice Brown; Leonard W Seymour; Kerry D Fisher
Journal:  Mol Ther       Date:  2015-12-28       Impact factor: 11.454

Review 3.  Stromal barriers and strategies for the delivery of nanomedicine to desmoplastic tumors.

Authors:  Lei Miao; C Michael Lin; Leaf Huang
Journal:  J Control Release       Date:  2015-08-12       Impact factor: 9.776

4.  ONCOLYTIC HERPES SIMPLEX VIRUS 1 (HSV-1) VECTORS: INCREASING TREATMENT EFFICACY AND RANGE THROUGH STRATEGIC VIRUS DESIGN.

Authors:  J Carson; D Haddad; M Bressman; Y Fong
Journal:  Drugs Future       Date:  2010       Impact factor: 0.148

5.  In Vivo Estimation of Oncolytic Virus Populations within Tumors.

Authors:  Mi-Yeon Jung; Chetan P Offord; Matthew K Ennis; Iris Kemler; Claudia Neuhauser; David Dingli
Journal:  Cancer Res       Date:  2018-08-16       Impact factor: 12.701

6.  Preclinical evaluation of a genetically engineered herpes simplex virus expressing interleukin-12.

Authors:  James M Markert; James J Cody; Jacqueline N Parker; Jennifer M Coleman; Kathleen H Price; Earl R Kern; Debra C Quenelle; Alfred D Lakeman; Trenton R Schoeb; Cheryl A Palmer; Samuel C Cartner; G Yancey Gillespie; Richard J Whitley
Journal:  J Virol       Date:  2012-02-29       Impact factor: 5.103

7.  Dynamics of melanoma tumor therapy with vesicular stomatitis virus: explaining the variability in outcomes using mathematical modeling.

Authors:  D M Rommelfanger; C P Offord; J Dev; Z Bajzer; R G Vile; D Dingli
Journal:  Gene Ther       Date:  2011-09-15       Impact factor: 5.250

8.  A dynamical systems model for combinatorial cancer therapy enhances oncolytic adenovirus efficacy by MEK-inhibition.

Authors:  Neda Bagheri; Marisa Shiina; Douglas A Lauffenburger; W Michael Korn
Journal:  PLoS Comput Biol       Date:  2011-02-17       Impact factor: 4.475

Review 9.  Combinatorial strategies for oncolytic herpes simplex virus therapy of brain tumors.

Authors:  Ryuichi Kanai; Samuel D Rabkin
Journal:  CNS Oncol       Date:  2013-03

Review 10.  "Buy one get one free": armed viruses for the treatment of cancer cells and their microenvironment.

Authors:  Balveen Kaur; Timothy P Cripe; E Antonio Chiocca
Journal:  Curr Gene Ther       Date:  2009-10       Impact factor: 4.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.